Sensor Bio adds remote monitoring veteran Ken Nelson to advisory board

Sensor Bio named digital health commercial leader Ken Nelson to its Advisory Board on July 9, 2026, tapping a veteran of BioTelemetry, iRhythm, Bardy Diagnostics, and Guidant/Boston Scientific as the company pushes deeper into healthcare, research, and enterprise markets. The move adds a seasoned operator with experience scaling cardiac monitoring businesses through IPOs and major acquisitions.

Why it matters: - Sensor Bio is adding a veteran commercial operator as it expands beyond its core platform and into new customer segments. - Ken Nelson brings experience scaling remote patient monitoring businesses through IPOs, acquisitions, and global commercial launches. - The appointment signals Sensor Bio’s push to strengthen go-to-market execution, channel development, and clinical adoption.

What happened: - Sensor Bio announced July 9, 2026, that Ken Nelson joined its Advisory Board. - Nelson has 25 years of experience across medical devices, wearables, and remote patient monitoring. - Nelson is a former leader at Guidant/Boston Scientific, BioTelemetry, iRhythm, Bardy Diagnostics, and Biotronik.

The details: - Nelson served as Global VP of Sales at BioTelemetry, which Philips acquired for $2.8 billion. - Nelson was VP of Sales and Marketing at iRhythm and helped build the teams that launched and commercialized the Zio Patch. - Nelson served as Chief Commercial Officer at Bardy Diagnostics, which Hillrom/Baxter acquired for more than $400 million. - Nelson also led digital health, diagnostics, and monitoring at Biotronik. - Nelson founded Nelson Jennings Ventures and is a Venture Partner at Star51 Capital. - Nelson sits on the boards of HeartBeam, Echo IQ, Acarix, Epitel, and Happitech. - Nelson has advisory roles with the Heart Rhythm Society, the American Heart Association, and MedTech Innovator. - Sensor Bio is headquartered in Austin, Texas. - Sensor Bio describes itself as a clinical-grade continuous biometric monitoring platform for health systems, researchers, and enterprise partners. - The company says its platform is backed by more than 29 peer-reviewed studies and research collaborations with NASA, Stanford, the NIH, and Orlando Health. - Nelson said Sensor Bio is positioned to move care from episodic snapshots to continuous insight across the body. - Nelson said the platform combines validated, research-grade biometrics with a buildable infrastructure for health systems, researchers, and enterprise partners. - Bruce Smith, Sensor Bio’s CEO, said Nelson has helped launch and scale leading remote patient monitoring companies from startup through IPO and multibillion-dollar acquisition.

Between the lines: - Sensor Bio is pairing product development with a commercial adviser who has already navigated the market paths the company may want to follow. - The board appointment also adds external credibility as Sensor Bio targets healthcare, research, and enterprise buyers that often want clinical evidence and proven commercialization.

What's next: - Sensor Bio said Nelson will advise as the company expands across healthcare, research, and enterprise verticals. - Nelson is expected to contribute on go-to-market strategy, channel development, and clinical adoption. - Sensor Bio’s broader positioning suggests the company will keep leaning on peer-reviewed evidence and research partnerships as it scales.

The bottom line: - Sensor Bio is betting that commercial experience matters as much as clinical validation when a monitoring platform tries to scale globally. - The Nelson appointment gives the company both operating credibility and market access guidance at a pivotal growth stage.

More information is available on Sensor Bio's LinkedIn page.